Stryker (SYK) AGM 2025 summary
Event summary combining transcript, slides, and related documents.
AGM 2025 summary
8 Jan, 2026Opening remarks and agenda
Meeting opened with reminders about forward-looking statements and non-GAAP measures, and confirmation of quorum for official proceedings.
Recognition of long-serving board members and introduction of current directors and executive leadership, including recent transitions.
Board and executive committee updates
Allan Golston retired from the board after 14 years; Manny Maceda nominated as a new director.
Leadership changes included new appointments for Chief Communications Officer, Chief Financial Officer, Corporate Secretary, and VP Assurance and Risk Advisory.
Shareholder proposals
Seven proposals presented, including director elections, auditor ratification, amendments to incentive and stock purchase plans, executive compensation, and a shareholder proposal on political spending.
Shareholder proposal on political spending dismissed due to absence of proponent.
Latest events from Stryker
- Definitive additional proxy materials filed for shareholder voting, with no fee required.SYK
Proxy filing23 Mar 2026 - Virtual meeting to elect directors, ratify auditor, and approve pay amid strong 2025 results.SYK
Proxy filing23 Mar 2026 - Strategy targets digital, M&A, and margin gains, with double-digit EPS growth through 2028.SYK
Investor Day 20253 Feb 2026 - Q2 organic sales up 9%, adjusted EPS up 10.6%, and guidance raised on strong demand.SYK
Q2 20242 Feb 2026 - Double-digit growth, record Mako installs, and strong 2026 outlook despite tariff headwinds.SYK
Q4 20252 Feb 2026 - Mako innovation, easing pricing, and new launches drive growth and share gains into 2025.SYK
2024 Wells Fargo Healthcare Conference22 Jan 2026 - Q3 net sales up 11.9% and adjusted EPS up 16.7%, with strong 2024 outlook and M&A momentum.SYK
Q3 202418 Jan 2026 - Double-digit organic growth and margin expansion, with portfolio moves and Spine impairments.SYK
Q4 20249 Jan 2026 - 2025 targets 8%-9% growth, margin expansion, and innovation through ASC, robotics, and M&A.SYK
Citi’s 2025 Medtech and Life Sciences Access Day7 Jan 2026